China Gathers Research Intelligence For Next Five-Year Plan
This article was originally published in PharmAsia News
Executive Summary
The organizers of 863 Program recently held a strategic seminar on biomedical devices, biochips and nano-biotechnology for China's 12th five-year plan. Experts analyzed the world's development trends of these fields, examined key local academic institutions' research directions, as well as forecast the major requirements and progress of the sector during the five-year plan. Top executives from venture capitalists Morgan Stanley, WI Harper Group and Japan's SoftBank pointed out that China's life sciences research focus is in line with global market trends. They suggested that the next step should emphasize the commercialization of scientific achievements and their clinical applications. (Click here for more - Chinese Language)
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.